Compare · AMAG vs EARS
AMAG vs EARS
Side-by-side comparison of AMAG Pharmaceuticals, Inc. (AMAG) and Auris Medical Holding Ltd. (EARS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMAG and EARS operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- AMAG Pharmaceuticals, Inc.
- Auris Medical Holding Ltd.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Latest AMAG
- Landsdowne Labs Names Bryan Laulicht CEO
- Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
- Covis Group Completes Acquisition of AMAG Pharmaceuticals
- Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Contango Oil & Gas Company, Eaton Vance Corp., MobileIron, Inc., Seacoast Commerce Banc Holdings, Perceptron, Inc., Standard AVB Financial Corp., Virginia National Bankshares Corporation and Virtusa Corporation
- ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - VRTU, AMAG, EV, CBMG
- Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Eaton Vance Corp., MobileIron, Inc., and Seacoast Commerce Banc Holdings
Latest EARS
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
- Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
- Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- SEC Form EFFECT filed by Auris Medical Holding Ltd.
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning